Success Metrics

Clinical Success Rate
87.2%

Based on 150 completed trials

Completion Rate
87%(150/172)
Active Trials
64(20%)
Results Posted
3%(4 trials)
Terminated
22(7%)

Phase Distribution

Ph phase_3
8
3%
Ph not_applicable
157
50%
Ph phase_4
10
3%
Ph phase_1
4
1%
Ph phase_2
7
2%

Phase Distribution

4

Early Stage

7

Mid Stage

18

Late Stage

Phase Distribution186 total trials
Phase 1Safety & dosage
4(2.2%)
Phase 2Efficacy & side effects
7(3.8%)
Phase 3Large-scale testing
8(4.3%)
Phase 4Post-market surveillance
10(5.4%)
N/ANon-phased studies
157(84.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.9%

150 of 181 finished

Non-Completion Rate

17.1%

31 ended early

Currently Active

64

trials recruiting

Total Trials

315

all time

Status Distribution
Active(76)
Completed(150)
Terminated(31)
Other(58)

Detailed Status

Completed150
unknown57
Recruiting50
Terminated22
Active, not recruiting14
Not yet recruiting12

Development Timeline

Analytics

Development Status

Total Trials
315
Active
64
Success Rate
87.2%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (2.2%)
Phase 27 (3.8%)
Phase 38 (4.3%)
Phase 410 (5.4%)
N/A157 (84.4%)

Trials by Status

withdrawn93%
active_not_recruiting144%
suspended10%
recruiting5016%
not_yet_recruiting124%
unknown5718%
completed15048%
terminated227%

Recent Activity

Clinical Trials (315)

Showing 20 of 315 trialsScroll for more
NCT03003572

Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity

Recruiting
NCT02908048

Extracellular RNA Markers of Liver Disease and Cancer

Terminated
NCT06037460Phase 3

TocilizuMab discontinuAtion in GIant Cell Arteritis

Active Not Recruiting
NCT05306912Not Applicable

Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules

Recruiting
NCT04222335Not Applicable

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Active Not Recruiting
NCT03892785Phase 3

MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

Active Not Recruiting
NCT05030038

Oral Aromatase Inhibitors Modify the Gut Microbiome

Recruiting
NCT02529085Not Applicable

PWS European Blood Bank for Infants and Controls From 0 to 48 Months

Completed
NCT05981326Not Applicable

Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer Patients

Recruiting
NCT06435546Not Applicable

Adherence to Oral Therapies in Advanced Breast and Prostate Cancers

Completed
NCT03798860

Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Completed
NCT06694363

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

Recruiting
NCT03252912Not Applicable

Study in Leptomeningeal Metastases of Breast Cancer

Completed
NCT02860260Not Applicable

Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke

Completed
NCT04953312Not Applicable

Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)

Withdrawn
NCT07460700Not Applicable

Mesenteric Ischemia Markers Study

Recruiting
NCT03187743Not Applicable

Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone

Completed
NCT02484274Not Applicable

Iron Deficiency (ID) in Infants

Completed
NCT06996249

Prospective Data Collection Initiative on Thoracic Malignancies

Recruiting
NCT07430566Not Applicable

Trauma Exposure and Suicidal Behaviors in Adolescents Aged 11-17 Hospitalized in Child and Adolescent Psychiatry

Not Yet Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
315